References
- World Health Organization. Ebola virus disease [Internet]. 2015; Available from: http://www.who.int/mediacentre/factsheets/fs103/en/
- Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet [Internet] 2003; 362:1953-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14683653; PMID:14683653; http://dx.doi.org/10.1016/S0140-6736(03)15012-X
- Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog [Internet] 2007; 3:e2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17238284; PMID:17238284; http://dx.doi.org/10.1371/journal.ppat.0030002
- Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet [Internet] 2010; 375:1896-905. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20511019; PMID:20511019; http://dx.doi.org/10.1016/S0140-6736(10)60357-1
- Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, Daddario-DiCaprio KM, Cassell GH, Jahrling PB, Geisbert TW. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis [Internet] 2007; 196 Suppl :S390-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17940975; PMID:17940975; http://dx.doi.org/10.1086/520598
- Olinger Jr. GG, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A [Internet] 2012; 109:18030-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23071322; PMID:23071322; http://dx.doi.org/10.1073/pnas.1213709109
- Pettitt J, Zeitlin L, Kim do H, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med [Internet] 2013; 5:199ra113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23966302; PMID:23966302
- Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med [Internet] 2012; 4:138ra81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22700957; PMID:22700957
- Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature [Internet] 2014; 514:47-53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25171469; PMID:25171469
- Qiu X, Wong G, Fernando L, Audet J, Bello A, Strong J, Alimonti JB, Kobinger GP. mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med [Internet] 2013; 5:207ra143. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24132638; PMID:24132638
- Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van Tongeren SA, Garza NL, Dong L, Mourich D V, Crumley S, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med [Internet] 2010; 16:991-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20729866; PMID:20729866; http://dx.doi.org/10.1038/nm.2202
- Gallagher J. Ebola: Experimental drug ZMapp is “100% effective” in animal trials [Internet]. BBC News 2014; Available from: http://www.bbc.com/news/health-28980153
- Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies. Curr Pharm Biotechnol [Internet] 2008 [cited 2015 Aug 3]; 9:447-67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19075685; PMID:19075685; http://dx.doi.org/10.2174/138920108786786367
- Ó'Fágáin C. Engineering protein stability. In: Walls D, Loughran ST, editors. Protein Chromatography. Springer New York Dordrecht Heidelberg London; 2011. page 103-36.
- Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. MAbs [Internet] 2011; 3:243-52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21406966; PMID:21406966; http://dx.doi.org/10.4161/mabs.3.3.15234
- Giudicelli V, Chaume D, Lefranc M-P. IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 2005; 33:D256-61; PMID:15608191; http://dx.doi.org/10.1093/nar/gki010
- Honegger AM, Plückthun A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol 2001; 309:657-70; PMID:11397087; http://dx.doi.org/10.1006/jmbi.2001.4662
- Janda A, Eryilmaz E, Nakouzi A, Cowburn D, Casadevall A. Variable region identical immunoglobulins differing in isotype express different paratopes. J Biol Chem [Internet] 2012; 287:35409-17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22930758; PMID:22930758; http://dx.doi.org/10.1074/jbc.M112.404483
- Buchanan A, Clementel V, Woods R, Harn N, Bowen M a., Mo W, Popovic B, Bishop SM, Dall'Acqua W, Minter R, et al. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. MAbs 2013; 5:255-62; PMID:23412563; http://dx.doi.org/10.4161/mabs.23392
- Yigzaw Y, Hinckley P, Hewig A, Vedantham G. Ion exchange chromatography of proteins and clearance of aggregates. Curr Pharm Biotechnol [Internet] 2009; 10:421-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19519418; PMID:19519418; http://dx.doi.org/10.2174/138920109788488842
- Lu Y, Williamson B, Gillespie R. Recent advancement in application of hydrophobic interaction chromatography for aggregate removal in industrial purification process. Curr Pharm Biotechnol [Internet] 2009; 10:427-33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19519419; PMID:19519419; http://dx.doi.org/10.2174/138920109788488897
- Gagnon P. Purification Tools for Monoclonal Antibodies. 1st ed. Tucson (AZ); Validated Biosystems Inc. 1996; 252p.
- He F, Phan DH, Hogan S, Bailey R, Becker GW, Narhi LO, Razinkov VI. Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence. J Pharm Sci [Internet] 2010; 99:2598-608. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20039384; PMID:20039384
- Brader ML, Estey T, Bai S, Alston RW, Lucas KK, Lantz S, Landsman P, Maloney KM. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Mol Pharm [Internet] 2015; 12:1005-17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25687223; PMID:25687223; http://dx.doi.org/10.1021/mp400666b
- Gillespie R, Nguyen T, Macneil S, Jones L, Crampton S, Vunnum S. Cation exchange surface-mediated denaturation of an aglycosylated immunoglobulin (IgG1). J Chromatogr A [Internet] 2012; 1251:101-10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22771262; PMID:22771262; http://dx.doi.org/10.1016/j.chroma.2012.06.037
- Mueller M, Loh MQ, Tscheliessnig R, Tee DH, Tan E, Bardor M, Jungbauer A. Liquid formulations for stabilizing IgMs during physical stress and long-term storage. Pharm Res [Internet] 2013; 30:735-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23143394; PMID:23143394; http://dx.doi.org/10.1007/s11095-012-0914-2
- Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 2009; 106:11937-42; PMID:19571001; http://dx.doi.org/10.1073/pnas.0904191106
- Barsoum J. Introduction of stable high-copy-number DNA into Chinese hamster ovary cells by electroporation. DNA Cell Biol [Internet] 1990 [cited 2015 Aug 5]; 9:293-300. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2112395; PMID:2112395; http://dx.doi.org/10.1089/dna.1990.9.293
- Rogers RS, Nightlinger NS, Livingston B, Campbell P, Bailey R, Balland A. Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics. MAbs [Internet] 2015:00-00. PMID:26186204; http://dx.doi.org/10.1080/19420862.2015.1069454